Introduction {#Sec1}
============

Several concerns have been raised by recently published meta-analyses (2014--2015) comparing coronary artery bypass surgery (CABG) with percutaneous coronary intervention (PCI) in patients with type 2 diabetes mellitus (T2DM). For example, Bangalore et al. \[[@CR1]\] recently published the results of a network meta-analysis, which led them to conclude that mortality following CABG was similar to that following PCI in patients with diabetes mellitus. However, Toeg et al. found that conclusion to be highly problematic and pointed to the results of their own meta-analysis \[[@CR2]\]; in response, Bangalore et al. \[[@CR3]\] defended their results and pointed out certain limitations of Toeg et al.'s meta-analysis. Aside from this particular controversial issue, other meta-analyses in this field have also reached divergent conclusions \[[@CR4], [@CR5]\].

Given this controversy as well as recent developments in interventional cardiology and the recent introduction of new guidelines for antiplatelet therapies (with new participants being treated based on those recent guidelines), in the work reported in the present paper, we aimed to systematically re-assess the important issue of whether PCI should be recommended over CABG or vice versa using data from the most recent cohort of T2DM patients (2015--2017).

Methods {#Sec2}
=======

Data Sources {#Sec3}
------------

Only an electronic search was carried out (no manual search). The following databases were searched: MEDLINE (including PubMed); Cochrane Database; EMBASE database; Google Scholar; official websites of several common cardiology journals.

Search Terms {#Sec4}
------------

The main search terms were 'diabetes mellitus,' 'coronary artery bypass surgery,' and 'percutaneous coronary intervention.' Other terms searched for included 'coronary angioplasty,' 'cardiac surgery,' 'type 2 diabetes mellitus,' and abbreviations such as CABG and PCI.

Outcomes {#Sec5}
--------

The following outcomes (Table [1](#Tab1){ref-type="table"}) were compared: mortality; myocardial infarction (MI); repeat revascularization (RR); stroke; major adverse events (MAEs), which refers to major adverse cardiac events and cerebrovascular events (including death, MI, RR, and/or stroke).Table 1Outcomes, diseases of the participants, and follow-up periods for each of the studies considered in this workStudyOutcomesDiseases of the participantsFollow-up period (years)Barber et al. \[[@CR8]\]MAEs, mortality, MI, stroke, RRT2DM and MVD3.8Bangalore et al. \[[@CR9]\]MI, RR, mortalityT2DM and MVD4Ben-Gal et al. \[[@CR10]\]MAEs, mortality, cardiac death, MI, RR, strokeT2DM and MVD with NSTEMI1Li et al. \[[@CR11]\]Mortality, MI, RR, stroke, MAEsDiabetic nephropathy and LMCAD4.3Marui et al. \[[@CR12]\]Mortality, cardiac death, MI, stroke, MI, RRT2DM and CAD5Naito et al. \[[@CR13]\]Mortality, cardiac deathT2DM and MVD3.7Li et al. \[[@CR14]\]Mortality, MI, RR, stroke, MAEsT2DM and CAD5Ramanathan et al. \[[@CR15]\]Mortality, MI, RR, stroke, MAEsT2DM and ACS5*MAEs* major adverse events, *MI* myocardial infarction, *RR* repeat revascularization, *T2DM* type 2 diabetes mellitus, *CAD* coronary artery disease, *NSTEMI* non-ST segment elevation myocardial infarction, *MVD* multi-vessel coronary disease, *LMCAD* left main coronary artery disease, *ACS* acute coronary syndrome

Follow-up Periods {#Sec6}
-----------------

The follow-up period varied from 1 to 5 years. However, most of the studies had a follow-up period of more than 3 years, as shown in Table [1](#Tab1){ref-type="table"}.

Data Extraction and Review {#Sec7}
--------------------------

The reviewers who were involved in the data extraction process were Xia Dai, Zu-chun Luo, Lu Zhai, Wen-piao Zhao, and Feng Huang. Data extracted included: type of study; total number of patients treated with CABG; total number of patients treated with PCI; year of publication (2015--2017); diseases of the participants; baseline features; outcomes and corresponding numbers of events; follow-up periods. Any disagreement was resolved by consensus.

The trials were assessed for risk of bias with reference to the Cochrane Collaboration \[[@CR6]\]. Approximate grades of between A and E were allotted to the trials depending on their risk of bias; A corresponded to a low risk of bias, whereas E indicated a high risk.

Statistical Analysis {#Sec8}
--------------------

The software used for statistical analysis was RevMan version 5.3. The analytical parameters of most interest were the odds ratios (OR) with 95% confidence intervals (CIs). Heterogeneity was assessed using two tests \[[@CR6]\]:*Q* statistic test: *P* \< 0.05 was considered to indicate a statistically significant result*I*^2^ statistic test: the higher the percentage value of *I*^2^, the greater the heterogeneity

In terms of the statistical model applied, a fixed effects model was used if *I*^2^ was \< 50%, and a random effects model was used if *I*^2^ was \> 50%. Sensitivity analysis was carried out using an exclusion method whereby multiple analyses were performed, with a different trial/observational study excluded in each analysis. Publication bias was assessed by observing the shape of the funnel plot.

Compliance with Ethics Guidelines {#Sec9}
---------------------------------

This meta-analysis is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec10}
=======

Search Results and General and Baseline Features {#Sec11}
------------------------------------------------

Figure [1](#Fig1){ref-type="fig"} presents the study selection procedure for this analysis (the PRISMA guideline was followed \[[@CR7]\]). Eight studies were ultimately included in the analysis \[[@CR8]--[@CR15]\].Fig. 1Flow diagram showing the study selection process

A total of 13,114 patients with T2DM were included in this meta-analysis (5502 patients were treated with CABG and 7612 patients were treated with PCI), as shown in Table [2](#Tab2){ref-type="table"}.Table 2General features of the studies included in the analysisStudyType of studyYear of publicationNo. of patients treated with CABG (*n*)No. of patients treated with PCI (*n*)Barber et al. \[[@CR8]\]RCT2016894949Bangalore et al. \[[@CR9]\]OS2015773773Ben-Gal et al. \[[@CR10]\]RCT20154231349Li et al. \[[@CR11]\]OS20175346Marui et al. \[[@CR12]\]OS20158611123Naito et al. \[[@CR13]\]OS2016227256Li et al. \[[@CR14]\]OS2017406406Ramanathan et al. \[[@CR15]\]OS201718652710Total no. of patients (*n*)55027612*RCT* randomized controlled trial, *OS* observational study, *CABG* coronary artery bypass surgery, *PCI* percutaneous coronary intervention

The baseline characteristics of the patients are presented in Table [3](#Tab3){ref-type="table"}.Table 3Baseline characteristics of the participantsStudiesAge (years)Males (%)HTN (%)Ds (%)Cs (%)Type of DESC/PC/PC/PC/PC/PBarber et al. \[[@CR8]\]64.1/64.867.9/69.787.7/87.984.1/84.214.6/13.6DESBangalore et al. \[[@CR9]\]64.7/64.968.0/68.0------EESBen-Gal et al. \[[@CR10]\]65.0/65.073.0/66.379.4/85.961.8/72.724.0/21.0DESLi et al. \[[@CR11]\]71.5/72.973.6/89.188.7/91.350.0/54.067.9/41.3DES\*Marui et al. \[[@CR12]\]67.8/68.773.0/68.084.0/88.0--25.0/25.0DESNaito et al. \[[@CR13]\]72.7/72.768.3/78.174.0/77.068.7/76.662.6/58.6DESLi et al. \[[@CR14]\]42.1/41.489.2/94.365.8/57.2--62.1/72.8DESRamanathan et al. \[[@CR15]\]65.2/67.373.2/72.091.8/88.179.5/77.5--DES*C* coronary artery bypass surgery, *P* percutaneous coronary intervention, *HTN* hypertension, *Ds* dyslipidemia, *Cs* current smokers, *EES* everolimus-eluting stents, *DES* drug-eluting stents, *DES\** drug-eluting stents with the inclusion of a small percentage of bare metal stents

Main Results of this Analysis {#Sec12}
-----------------------------

This analysis---which only included trials and observational studies published after the year 2014---showed that during follow-up periods ranging from 1 to 5 years, mortality in T2DM patients treated with CABG was not significantly different from that in T2DM patients treated with PCI (OR 0.90, 95% CI 0.61--1.31; *P* = 0.57, as shown in Fig. [2](#Fig2){ref-type="fig"}). Stroke rates were also similar in the two groups (OR 1.24, 95% CI 0.78--1.99; *P* = 0.36). However, the rate of MAEs was significantly higher in the PCI group (OR 0.63, 95% CI 0.48--0.82; *P* = 0.0006, as shown in Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Comparison of adverse outcomes in CABG versus PCI patients with T2DM (part I)

The rates of cardiac death in the two groups were not significantly different (OR 1.00, 95% CI 0.78--1.30; *P* = 0.98). However, the rates of repeat revascularization and MI were significantly more favorable with CABG than with PCI (OR 0.27, 95% CI 0.24--0.30; *P* = 0.00001 and OR 0.40, 95% CI 0.35--0.47; *P* = 0.00001, respectively, as shown in Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Comparison of adverse outcomes in CABG versus PCI patients with T2DM (part II)

When a sensitivity analysis was carried out, the results showed that the findings of this analysis were not excessively influenced by any of the studies. There was also little evidence of publication bias.

Discussion {#Sec13}
==========

Recently, several issues have been raised as a result of comparisons of the adverse outcomes of CABG with those of PCI in patients with T2DM \[[@CR1]\]. Mortality was reported to be similar in PCI and CABG patients with T2DM, which was seen as a problematic conclusion. Therefore, in the present analysis, we recompared the outcomes of PCI and CABG using data from recently published studies of T2DM patients in order to check this conclusion.

The results of the present analysis show that during follow-up periods ranging from 1 to 5 years, all-cause mortality and the rate of cardiac death in T2DM patients treated with CABG were not significantly different from those in T2DM patients treated with PCI. However, the rate of MAEs (including MI and RR) was significantly higher with PCI. The difference in stroke rate between the groups was not statistically significant.

Patients with T2DM are more at risk of in-stent restenosis following PCI, even during a medium-term rather than long-term follow-up period, which contributes to the significantly higher MAE rate compared to T2DM patients treated with CABG. The incidence of both occlusive and nonocclusive re-stenosis has been shown to be higher in uncontrolled DM patients. Even if diabetes mellitus is independently associated with adverse outcomes following PCI, insulin treatment and the severity of this chronic disease may be other causes of adverse outcomes.

This analysis of newly published data supports the results obtained by Bangalore et al. \[[@CR1]\], suggesting that their conclusion is not "problematic." Even though they carried out a network meta-analysis, which performed indirect comparisons, the results of the present analysis---which involved direct comparisons---did not show any significant difference from their results.

A recent publication in*Scientific Reports* \[[@CR16]\] also presented similar results to the current analysis, even though it did not specifically include patients with T2DM. No difference in mortality between patients treated with an everolimus-eluting stent (EES) and those treated with CABG was observed, whereas EES was associated with a significantly higher rate of major adverse cardiovascular events than CABG. In addition, in a study focusing on patients with multi-vessel coronary disease and severe left ventricular systolic dysfunction, long-term mortality in the PCI and CABG groups was comparable, whereas the PCI group was associated with significantly higher rates of MI and repeat revascularization \[[@CR17]\].

Results of other studies in which a significantly higher mortality was associated with PCI in T2DM patients than with CABG in T2DM patients could be due to the use of insulin treatment, as previously stated \[[@CR18]\].

Nevertheless, the selection of patients for CABG or PCI should be partly based on their SYNTAX scores, especially for patients with T2DM, since they may have other comorbidities. Even though CABG should be considered the optimal revascularization strategy, PCI could be more applicable to a few patients according to their SYNTAX scores. The application of the SYNTAX score in interventional cardiology should be encouraged \[[@CR19]\].

Limitations {#Sec14}
-----------

This study has a number of limitations. First, the total number of patients was not high enough to reach a definitive conclusion. Second, patient data from randomized trials and observational studies were combined and analyzed. Third, the follow-up periods varied between studies. Fourth, the diseases (e.g., left main coronary artery disease, multi-vessel disease, diabetic nephropathy) suffered by the participants varied. Finally, the data were adjusted to represent less heterogeneity.

Conclusions {#Sec15}
===========

During follow-up periods of 1--5 years, mortality in T2DM patients treated with CABG did not differ significantly from mortality in T2DM patients treated with PCI. However, the rate of other major adverse events was significantly higher in the CABG group compared to the PCI group.
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